RxDoctor Payments Data

Linda Burns, DO

Internal Medicine · Orchard Park, NYNPI 1205082666

Payments from drug & device makers

$85,033in general payments, 2019–2025

Across 377 payments — averaging $225.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$67K
  • Janssen Research & Development, LLC$12K
  • Amgen$977
  • Novartis$801
  • Pfizer$699
  • AbbVie$684
  • plus $3K from 22 others
$114in research payments, 2019–2025

Across 1 payment — averaging $114.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$114

What the payments were for

  • Food & beverage$5,68899%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$85,033 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$2,008,049
Medicare patients
531
Services billed
98,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept132$1,252,319
Humira(Cf) PenAdalimumab41$499,328
RinvoqUpadacitinib40$312,912
ArcalystRilonacept13$289,136
Xeljanz XrTofacitinib Citrate36$198,447
HumiraAdalimumab19$179,582
Actemra ActpenTocilizumab33$152,299
SimponiGolimumab19$150,437
Cimzia (2 Pack)Certolizumab Pegol21$143,432
Humira PenAdalimumab16$125,139
OtezlaApremilast15$122,163
Taltz AutoinjectorIxekizumab18$121,327
OrenciaAbatacept22$117,688
EnbrelEtanercept17$114,121
Teriparatide13$51,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$684$492,49359 claims
AmgenOtezla, Enbrel$977$236,28432 claims
Johnson & JohnsonSimponi$434$150,43719 claims
UCB, Inc.Cimzia (2 Pack)$287$143,43221 claims
E.r. Squibb & Sons, L.L.C.Orencia$354$117,68822 claims
Lilly USA, LLCOlumiant$180$35,62013 claims
PfizerAbrysvo$699$3,23411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →